Comparison of Tyrosinase Antibody, Tyrosinase-Related Protein-1 And-2 Antibodies, Melanin-Concentrating Hormone Receptor Antibody Levels With Autologous Serum Skin Test and Autologous Plasma Skin Test Results in Patients With Vitiligo

dc.contributor.author Unal, Abdullah
dc.contributor.author Ozkol, Hatice Uce
dc.contributor.author Bayram, Yasemin
dc.contributor.author Akdeniz, Necmettin
dc.date.accessioned 2025-05-10T17:59:32Z
dc.date.available 2025-05-10T17:59:32Z
dc.date.issued 2021
dc.description.abstract Introduction: Although the exact etiopathogenesis of vitiligo is unknown, the autoimmunity hypothesis is much in evidence. The autologous serum skin test (ASST) and autologous plasma skin test (APST) are in vivo methods used in the diagnosis of some autoimmune diseases, which are easy and inexpensive to perform. Aim: In this study, we investigated whether or not ASST and APST could determine autoimmunity in patients with vitiligo. Material and methods: In this study, 30 vitiligo patients presenting to the dermatology outpatient clinic and 30 healthy volunteers without any known autoimmune diseases were included. Antibodies such as tyrosinase, tyrosinase-related protein-1 (TYRP1), tyrosinase-related protein-2 (TYRP2) and melanin-concentrating hormone receptor 1 (MCHR1) antibodies determined to be associated with vitiligo were examined. In addition, the association of these antibodies with the positivity of ASST and APST, which were suggested to be associated with autoimmunity, were examined. Results: In our study, tyrosinase antibody was found to be significantly higher in vitiligo patients. ASST was positive in 12 (40%) patients with vitiligo and 8 (26.6%) control subjects. APST was positive in 8 (26.6%) of the patients with vitiligo and in 2 (6.6%) of the controls, and there was a significant difference between the groups in terms of APST positivity (p = 0.032). In addition, in our study, a significant correlation was found between TYRP1 antibody positivity and APST positivity in the patient group (p = 0.005). Conclusions: These findings suggest that we may use APST to investigate the autoimmune etiopathogenesis of vitiligo. en_US
dc.description.sponsorship Van YYU - BAP en_US
dc.description.sponsorship Van YYU - BAP provided financial support to this clinical trial. en_US
dc.identifier.doi 10.5114/ada.2020.93272
dc.identifier.issn 1642-395X
dc.identifier.issn 2299-0046
dc.identifier.scopus 2-s2.0-85112726310
dc.identifier.uri https://doi.org/10.5114/ada.2020.93272
dc.identifier.uri https://hdl.handle.net/20.500.14720/20565
dc.language.iso en en_US
dc.publisher Termedia Publishing House Ltd en_US
dc.relation.ispartof Postepy Dermatologii i Alergologii en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Vitiligo en_US
dc.subject Autoimmunity en_US
dc.subject Antibodies en_US
dc.subject Autologous Serum Skin Test en_US
dc.title Comparison of Tyrosinase Antibody, Tyrosinase-Related Protein-1 And-2 Antibodies, Melanin-Concentrating Hormone Receptor Antibody Levels With Autologous Serum Skin Test and Autologous Plasma Skin Test Results in Patients With Vitiligo en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.scopusid 57226793775
gdc.author.scopusid 54179576500
gdc.author.scopusid 23488098800
gdc.author.scopusid 56220714100
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Unal, Abdullah] Abdullah Unal Private Dermatol Clin, Istanbul, Turkey; [Ozkol, Hatice Uce] Yuzuncu Yil Univ, Dept Dermatol, Fac Med, TR-6510 Van, Turkey; [Bayram, Yasemin] Yuzuncu Yil Univ, Dept Microbiol, Fac Med, Van, Turkey; [Akdeniz, Necmettin] Medeniyet Univ, Dept Dermatol, Fac Med, Istanbul, Turkey en_US
gdc.description.endpage 479 en_US
gdc.description.issue 3 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 473 en_US
gdc.description.volume 38 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q4
gdc.identifier.pmid 34377130
gdc.identifier.wos WOS:000678928900019
gdc.index.type WoS
gdc.index.type Scopus

Files